NASDAQ:TNGX Tango Therapeutics Q3 2026 Earnings Report $21.90 -1.18 (-5.11%) Closing price 04:00 PM EasternExtended Trading$21.89 -0.01 (-0.05%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Tango Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.34Beat/MissN/AOne Year Ago EPSN/ATango Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$3.28 millionBeat/MissN/AYoY Revenue GrowthN/ATango Therapeutics Announcement DetailsQuarterQ3 2026Date11/3/2026TimeBefore Market OpensConference Call DateWednesday, November 4, 2026Conference Call Time9:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Tango Therapeutics Earnings HeadlinesTango Therapeutics Insider Sold Shares Worth $660,796, According to a Recent SEC Filing2 hours ago | marketscreener.comMHead-To-Head Analysis: GeoVax Labs (NASDAQ:GOVX) versus Tango Therapeutics (NASDAQ:TNGX)September 30, 2026 | americanbankingnews.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.October 6 at 1:00 AM | Porter & Company (Ad)Comparing Tango Therapeutics (NASDAQ:TNGX) and Syndax Pharmaceuticals (NASDAQ:SNDX)September 28, 2026 | americanbankingnews.comTango Therapeutics, Inc. (TNGX)September 27, 2026 | finance.yahoo.comIl principale responsabile contabile di Tango Therapeutics vende azioni per $198kSeptember 25, 2026 | it.investing.comSee More Tango Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tango Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tango Therapeutics and other key companies, straight to your email. Email Address About Tango TherapeuticsTango Therapeutics (NASDAQ:TNGX) is a clinical-stage biotechnology company focused on discovering and developing medicines that target cancer vulnerabilities and activate the immune system against tumors. The company uses functional genomics, including CRISPR-based screening, to identify genetic dependencies that may be selectively targeted in cancer cells while limiting effects on healthy tissue. Tango’s research and development programs include small-molecule therapies and immuno-oncology candidates designed to address genetically defined cancers. Its pipeline has included programs targeting MAT2A and other cancer-related pathways, as well as approaches intended to enhance the ability of T cells to recognize and destroy tumor cells. Headquartered in Boston, Massachusetts, Tango Therapeutics was founded in 2017 and has collaborated with Gilead Sciences on the discovery and development of cancer immunotherapies. The company is led by President and Chief Executive Officer Barbara Weber, M.D., and primarily serves the global biopharmaceutical and oncology markets through its research, clinical development and strategic partnerships.View Tango Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lamb Weston’s Turnaround Is Starting to Look RealAI Chip Demand Gives Linde a New Growth CatalystInvenTrust’s Sell-Off Opens a Potential Entry PointCuraleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02 Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
